SCHEMBL5038405

SCHEMBL5038405

CC(C)(C)OC(=O)CNCc1cccc(C(=O)O)c1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 5/20 0.60
NR1H4 Q96RI1 1/20 0.52
MYC P01106 1/20 0.47
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
FOLH1 Q04609 1/20 0.45
SLC7A5 Q01650 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
MRGPRX4 Q96LA9 5/20 0.44
HIF1A Q16665 1/20 0.44
FABP4 P15090 1/20 0.44
UNG P13051 1/20 0.44
TP53 P04637 2/20 0.43
PKM P14618 2/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
RAB9A P51151 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15876029 0.89 SLC7A5 (0.54) MEP1BNR1H4SLC7A5MRGPRX4HIF1A
SCHEMBL17486357 0.89 MEP1B (0.47) MEP1BNR1H4SLC7A5RAB9A
SCHEMBL1830056 0.88 LOXL2 (0.54) MEP1BFOLH1SLC7A5SMN1; SMN2MRGPRX4
Hydrochloric Acid SCHEMBL17433718 0.88 SLC7A5 (0.53) MEP1BNR1H4SLC7A5SMN1; SMN2MRGPRX4
SCHEMBL557761 0.87 MEP1B (0.51) MEP1BNR1H4MYCCA1CA2
SCHEMBL734928 0.84 ATM (0.55) CA1SMN1; SMN2
Hydrochloric Acid SCHEMBL28220743 0.84 TSHR (0.47) MEP1BNR1H4SLC7A5SMN1; SMN2MRGPRX4
SCHEMBL16355777 0.83 SLC7A5 (0.44) MEP1BCA1SLC7A5SMN1; SMN2RAB9A
SCHEMBL1243790 0.83 ALDH1A1 (0.51) NR1H4SMN1; SMN2
Hydrochloric Acid SCHEMBL6433307 0.83 ATM (0.53) CA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313703-B1 PRODRUGS TO NMDA RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2008-02-13 EP disclosed
EP-1313703-A1 PRODRUGS TO NMDA RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-28 EP disclosed
US-6407235-B1 A NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR-SUBTYPE SELECTIVE BLOCKERS; PRODRUGS HAVE IMPROVED SOLUBILITY AND ARE HYDROLYZED IN VIVO; FOR EXAMPLE, THE 4-AMINOMETHYL-BENZOIC ACID ESTER OF THE PHENOL, OR THE PHOSPHATE ESTER HOFFMANN-LA ROCHE INC. 2002-06-18 US disclosed
US-20020040037-A1 Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol EVOTEC INTERNATIONAL GMBH (DE) 2002-04-04 US disclosed
WO-2002016321-A1 PRODRUGS TO NMDA RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040037-A1 Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol HAO2, CYP2B6, CBR1 MEP1B 2341/4885NR1H4 350/4885MYC 3203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.